New York State Teachers Retirement System Sells 52,939 Shares of Kenvue Inc. $KVUE

New York State Teachers Retirement System lowered its stake in Kenvue Inc. (NYSE:KVUE) by 3.5% in the fourth quarter, Holdings Channel reports. The fund owned 1,465,972 shares of the company’s stock after selling 52,939 shares during the quarter. New York State Teachers Retirement System’s holdings in Kenvue were worth $25,288,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Kenvue by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock valued at $4,052,913,000 after buying an additional 1,604,040 shares during the period. American Century Companies Inc. increased its stake in shares of Kenvue by 22.4% in the third quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock valued at $601,267,000 after buying an additional 6,781,640 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Kenvue by 13.5% in the third quarter. Dimensional Fund Advisors LP now owns 23,127,234 shares of the company’s stock valued at $375,377,000 after buying an additional 2,747,952 shares during the period. Van ECK Associates Corp increased its stake in shares of Kenvue by 101.3% in the third quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock valued at $298,008,000 after buying an additional 9,240,434 shares during the period. Finally, Amundi increased its stake in shares of Kenvue by 21.6% in the third quarter. Amundi now owns 17,645,761 shares of the company’s stock valued at $277,012,000 after buying an additional 3,135,871 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $17.44 on Friday. The company has a market cap of $33.48 billion, a price-to-earnings ratio of 22.65, a price-to-earnings-growth ratio of 3.96 and a beta of 0.55. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66. The firm has a 50 day moving average of $17.72 and a 200-day moving average of $17.18.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.22 by $0.05. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The company had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. During the same quarter last year, the firm posted $0.26 EPS. The company’s quarterly revenue was up 3.2% on a year-over-year basis. On average, equities analysts forecast that Kenvue Inc. will post 1.1 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th will be paid a dividend of $0.2075 per share. The ex-dividend date is Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.8%. Kenvue’s dividend payout ratio (DPR) is 107.79%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. UBS Group lowered their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Canaccord Genuity Group upped their price objective on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. Citigroup lowered their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. Jefferies Financial Group downgraded Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the company from $23.00 to $18.00 in a research note on Friday, January 30th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a research note on Wednesday, April 8th. Three analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.